Company intelligence / Profile preview
Alden Cancer Therapy
Norwaypmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alden Cancer Therapy II has developed a dendritic cell-based immunotherapy for castration-resistant prostate cancer. Its lead program, ACT-2001, was evaluated in a completed Phase 1 clinical trial (NCT02423928), which combined cryotherapy and intra-tumoral immunotherapy using autologous immature dendritic cells in men with metastatic castration-resistant prostate cancer. The trial enrolled 20 patients and focused on safety and feasibility; detailed efficacy results are not publicly available[1].
- Therapeutic areas
- Oncology
- Modalities
- Dendritic cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alden Cancer Therapy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alden Cancer Therapy.